Urgent Need for Insurance Coverage of Advanced Prostate Cancer Treatments

Metastatic castration-resistant prostate cancer (mCRPC) presents severe clinical challenges as the disease advances beyond initial treatments, leaving patients with limited therapeutic options and mounting physical burdens, according to the Korean Prostate Cancer Patients Health Promotion Association. As cancer spreads to other organs, standard treatment efficacy wanes, prompting advocacy groups to push for broader healthcare access to emerging therapies.

The Clinical Burden of Metastatic Castration-Resistant Prostate Cancer

Prostate cancer is frequently characterized in its early stages as highly treatable, yielding favorable prognoses when detected promptly. However, according to the Korean Prostate Cancer Patients Health Promotion Association, progression to the metastatic stage fundamentally alters this trajectory. Patients diagnosed with mCRPC face shrinking treatment choices and shortened periods of therapeutic response, requiring them to endure repeated rounds of taxing chemotherapy. These regimens impose heavy physical strains that can exhaust patients, while the lack of predictable timelines compounds the psychological distress for both individuals and their families.

Radioligand Therapy and the Demand for National Health Insurance Coverage

Recent clinical developments have introduced radioligand therapy as an option for advanced prostate cancer patients. Clinical studies indicate that this targeted approach can reduce pain, extend overall survival, and delay the deterioration of quality of life compared to standard therapies. Despite these clinical benefits, high out-of-pocket costs create substantial barriers to access. Because many prostate cancer patients are retired or face depleted financial resources after years of medical care, non-reimbursed treatments remain financially out of reach for a significant portion of the patient population, according to the association.

Policy Implications for Advanced Cancer Care

Advocacy representatives emphasize that timely access to effective therapies is critical for extending both life expectancy and meaningful time spent with family. The Korean Prostate Cancer Patients Health Promotion Association has called for expedited discussions regarding national health insurance coverage for clinically proven treatments. Without public reimbursement, patients often confront prohibitive expenses that force difficult decisions regarding treatment continuation, underscoring the urgent need for structural policy adjustments to support advanced cancer care.